Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001206642 | SCV001377961 | pathogenic | Combined oxidative phosphorylation defect type 17 | 2022-11-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 937598). Disruption of this splice site has been observed in individual(s) with clinical features of mitochondrial complex I deficiency (PMID: 31045291). This variant is present in population databases (rs748684065, gnomAD 0.009%). This sequence change affects a donor splice site in intron 1 of the ELAC2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ELAC2 are known to be pathogenic (PMID: 27769300, 31045291). |
Gene |
RCV003223704 | SCV003919248 | pathogenic | not provided | 2022-10-20 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31045291) |
Revvity Omics, |
RCV001206642 | SCV004238170 | likely pathogenic | Combined oxidative phosphorylation defect type 17 | 2023-02-16 | criteria provided, single submitter | clinical testing |